H-VGRNFTNL-OH
Ref. 3D-PP46714
| 1mg | 207.00 € | ||
| 10mg | 240.00 € | ||
| 100mg | 423.00 € |
Product Information
- NH2-Val-Gly-Arg-Asn-Phe-Thr-Asn-Leu-OH
Peptide H-VGRNFTNL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-VGRNFTNL-OH include the following: Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes S Ugel , E Scarselli, M Iezzi , C Mennuni - Blood, The Journal , 2010 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/115/7/1374/26711 In vivo Administration of Artificial Antigen-Presenting Cells Activates Low-Avidity T Cells for Treatment of Cancer S Ugel , A Zoso, C De Santo , Y Li, I Marigo, P Zanovello - Cancer research, 2009 - AACRhttps://aacrjournals.org/cancerres/article-abstract/69/24/9376/551081 DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity S Peng , B Ma, SH Chen, CF Hung , TC Wu - Cell & bioscience, 2011 - Springerhttps://link.springer.com/article/10.1186/2045-3701-1-26 Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy MS Sasso, G Lollo , M Pitorre, S Solito, L Pinton - Biomaterials, 2016 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0142961216301156 Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer C Mennuni, S Ugel , F Mori, B Cipriani, M Iezzi - Cancer research, 2008 - AACRhttps://aacrjournals.org/cancerres/article-abstract/68/23/9865/540757 Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells B Molon, S Ugel , F Del Pozzo, C Soldani - Journal of Experimental , 2011 - rupress.orghttps://rupress.org/jem/article-abstract/208/10/1949/40937 Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer A Agostini , I Guerriero , G Piro , G Quero - Journal of Translational , 2023 - Springerhttps://link.springer.com/article/10.1186/s12967-023-04733-z
Chemical properties
Technical inquiry about: 3D-PP46714 H-VGRNFTNL-OH
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
